Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beauty Health (SKIN) Cash & Equivalents (2020 - 2026)

SkinHealth Systems has reported Cash & Equivalents over the past 6 years, most recently at $232.7 million for Q4 2025.

  • Quarterly Cash & Equivalents fell 37.13% to $232.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $232.7 million through Dec 2025, down 37.13% year-over-year, with the annual reading at $232.7 million for FY2025, 37.13% down from the prior year.
  • Cash & Equivalents was $232.7 million for Q4 2025 at SkinHealth Systems, up from $219.4 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $901.9 million in Q4 2021 and troughed at $2.8 million in Q1 2021.
  • The 5-year median for Cash & Equivalents is $483.8 million (2023), against an average of $469.1 million.
  • Year-over-year, Cash & Equivalents surged 2874388.0% in 2021 and then crashed 39.35% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $901.9 million in 2021, then tumbled by 37.0% to $568.2 million in 2022, then fell by 7.95% to $523.0 million in 2023, then fell by 29.25% to $370.1 million in 2024, then tumbled by 37.13% to $232.7 million in 2025.
  • Per Business Quant, the three most recent readings for SKIN's Cash & Equivalents are $232.7 million (Q4 2025), $219.4 million (Q3 2025), and $212.0 million (Q2 2025).